Abstract
The ubiquitin-proteasome pathway plays a central role in the degradation of proteins involved in several pathways including the cell cycle, cellular proliferation and apoptosis. Bortezomib is the first proteasome inhibitor to enter clinical use, and received approval by the Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma, therefore validating inhibition of the proteasome as an anticancer target. The approval of Bortezomib was based on a large, international, multicenter phase III trial showing its efficacy and safety compared with conventional therapy. Preclinical data also demonstrates the synergistic effect of bortezomib with other chemotherapeutic agents and its ability to overcome drug resistance. Since then several other proteasome inhibitors have been developed. The anti-tumor activities of bortezomib have been attributed to its effect on pro-apoptotic pathways including the inhibition of NF-κB and induction of endoplasmic reticulum stress. However, the molecular mechanisms are not fully understood. In this review, we will summarize the molecular mechanism of apoptosis by bortezomib.
Keywords: dependent proteolysis, proteasome, bortezomib-induced apoptosis, cyclin D1
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Volume: 7 Issue: 3
Author(s): Yuki Ishii, Samuel Waxman and Doris Germain
Affiliation:
Keywords: dependent proteolysis, proteasome, bortezomib-induced apoptosis, cyclin D1
Abstract: The ubiquitin-proteasome pathway plays a central role in the degradation of proteins involved in several pathways including the cell cycle, cellular proliferation and apoptosis. Bortezomib is the first proteasome inhibitor to enter clinical use, and received approval by the Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma, therefore validating inhibition of the proteasome as an anticancer target. The approval of Bortezomib was based on a large, international, multicenter phase III trial showing its efficacy and safety compared with conventional therapy. Preclinical data also demonstrates the synergistic effect of bortezomib with other chemotherapeutic agents and its ability to overcome drug resistance. Since then several other proteasome inhibitors have been developed. The anti-tumor activities of bortezomib have been attributed to its effect on pro-apoptotic pathways including the inhibition of NF-κB and induction of endoplasmic reticulum stress. However, the molecular mechanisms are not fully understood. In this review, we will summarize the molecular mechanism of apoptosis by bortezomib.
Export Options
About this article
Cite this article as:
Ishii Yuki, Waxman Samuel and Germain Doris, Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618180
DOI https://dx.doi.org/10.2174/187152007780618180 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine Inflammatory Cytokines Pathways as Potential Therapeutic Targets for Gastric Cancer
Current Cancer Therapy Reviews MicroRNA-490-5P Targets CCND1 to Suppress Cellular Proliferation in Glioma Cells and Tissue Through Cell Cycle Arrest
Current Neurovascular Research Graphical Abstracts
Letters in Drug Design & Discovery Hypericin and its Derivatives Act as Radiosensitizing Agents That Can Inhibit Tumor Initiating Cell Viability
Clinical Cancer Drugs Development of Selective High Affinity Antagonists, Agonists, and Radioligands for the P2Y1 Receptor
Combinatorial Chemistry & High Throughput Screening Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Endoplasmic Reticulum Stress and Bipolar Disorder - Almost Forgotten Therapeutic Drug Targets in the Unfolded Protein Response Pathway Revisited
CNS & Neurological Disorders - Drug Targets Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued)